Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Omontys (peginesatide) – for Treatment of Anaemia Associated with Chronic Kidney Disease

Drug (Brand / Generic)

Omontys / Peginesatide

Company

Affymax and Takeda Pharmaceutical Company

Therapy Class

Erythropoiesis-stimulating agent

Product Description

Synthetic peptide-based erythropoiesis-stimulating agent

Current Indication

Anaemia associated with chronic kidney disease

Market Sector

Anaemia

Development Status

Approved in the US, under review in Europe
Expand
Close
Close
Close

Go Top